Foroud Shahbazi PharmD

Assistant professor of pharmacotherapy, college of pharmacy, Kermanshah university of medical sciences.

Objectives

- Pharmacologic therapy for Covid-19
- Safety concerns consideration with hydroxychloroquine
- Major drug-drug interactions in Covid-19 treatment

•

References

- Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB.
 Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
 JAMA. 2020 Apr 13. doi: 10.1001/jama.2020.6019. [Epub ahead of print]
- Bhimraj, Adarsh, et al. "Infectious Diseases Society of America guidelines on the treatment and management of patients with COVID-19." (2020).

References

- Barlow A, Landolf KM, Barlow B, Yeung SY, Heavner JJ, Claassen CW, Heavner MS. Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2020 Apr 7.
- McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. InOpen Forum Infectious Diseases 2020 Apr (Vol. 7, No. 4, p. ofaa105). US: Oxford University Press.
- https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_Psychiatry_Guide/787387/all/Managing_Stress_and_Coping_with_COVID_19?q=covid
- Juurlink DN. Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection. CMAJ. 2020 Jan 1.